WO1993007905A3 - Treated apatite particles for medical diagnostic imaging - Google Patents

Treated apatite particles for medical diagnostic imaging Download PDF

Info

Publication number
WO1993007905A3
WO1993007905A3 PCT/US1992/009032 US9209032W WO9307905A3 WO 1993007905 A3 WO1993007905 A3 WO 1993007905A3 US 9209032 W US9209032 W US 9209032W WO 9307905 A3 WO9307905 A3 WO 9307905A3
Authority
WO
WIPO (PCT)
Prior art keywords
imaging
apatite particles
medical diagnostic
disclosed
magnetic resonance
Prior art date
Application number
PCT/US1992/009032
Other languages
French (fr)
Other versions
WO1993007905A2 (en
Inventor
Edward A Deutsch
Karen F Deutsch
William P Cacheris
William P Ralston
David H White
Steven R Woulfe
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Priority to JP5507914A priority Critical patent/JPH07500823A/en
Priority to EP92922461A priority patent/EP0610333B1/en
Priority to AU28864/92A priority patent/AU674291B2/en
Priority to AT92922461T priority patent/ATE198423T1/en
Priority to DE69231627T priority patent/DE69231627T2/en
Publication of WO1993007905A2 publication Critical patent/WO1993007905A2/en
Publication of WO1993007905A3 publication Critical patent/WO1993007905A3/en
Priority claimed from PCT/US1994/003276 external-priority patent/WO1995027437A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3925—Markers, e.g. radio-opaque or breast lesions markers ultrasonic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3954—Markers, e.g. radio-opaque or breast lesions markers magnetic, e.g. NMR or MRI
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/72—On an electrically conducting, semi-conducting, or semi-insulating substrate
    • Y10S977/722—On a metal substrate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/88—Manufacture, treatment, or detection of nanostructure with arrangement, process, or apparatus for testing
    • Y10S977/881—Microscopy or spectroscopy, e.g. sem, tem
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/91—Strengthening cell or tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/928—X-ray agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/929—Ultrasound contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/93—MRI contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for 19F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described apatite particles and then performing the medical diagnostic procedure.
PCT/US1992/009032 1991-10-22 1992-10-21 Treated apatite particles for medical diagnostic imaging WO1993007905A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP5507914A JPH07500823A (en) 1991-10-22 1992-10-21 Processed apatite particles for medical diagnostic imaging
EP92922461A EP0610333B1 (en) 1991-10-22 1992-10-21 Treated apatite particles for medical diagnostic imaging
AU28864/92A AU674291B2 (en) 1991-10-22 1992-10-21 Treated apatite particles for medical diagnostic imaging
AT92922461T ATE198423T1 (en) 1991-10-22 1992-10-21 TREATED APATITE PARTICLES FOR IMAGING IN MEDICAL DIAGNOSTICS
DE69231627T DE69231627T2 (en) 1991-10-22 1992-10-21 TREATED APATITE PARTICLES FOR IMAGE GENERATION IN MEDICAL DIAGNOSTICS

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78432591A 1991-10-22 1991-10-22
US784,325 1991-10-22
US07/948,540 US5344640A (en) 1991-10-22 1992-09-22 Preparation of apatite particles for medical diagnostic imaging
US948,540 1992-09-22
PCT/US1994/003276 WO1995027437A1 (en) 1991-10-22 1994-04-11 Microfluidization of calcium/oxyanion-containing particles

Publications (2)

Publication Number Publication Date
WO1993007905A2 WO1993007905A2 (en) 1993-04-29
WO1993007905A3 true WO1993007905A3 (en) 1993-08-05

Family

ID=27120269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009032 WO1993007905A2 (en) 1991-10-22 1992-10-21 Treated apatite particles for medical diagnostic imaging

Country Status (9)

Country Link
US (4) US5344640A (en)
EP (1) EP0610333B1 (en)
JP (1) JPH07500823A (en)
AT (1) ATE198423T1 (en)
AU (2) AU674291B2 (en)
CA (1) CA2120130A1 (en)
DE (1) DE69231627T2 (en)
ES (1) ES2152932T3 (en)
WO (1) WO1993007905A2 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205298A (en) * 1991-09-17 1993-05-01 Steven Carl Quay GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA
ES2145011T5 (en) * 1991-09-17 2008-02-01 Ge Healthcare As GAS CONTRAST MEANS FOR ECOGRAPHIES.
US5407659A (en) * 1991-10-22 1995-04-18 Mallinckrodt Medical, Inc. Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5560902A (en) * 1991-10-22 1996-10-01 Mallinckrodt Medical, Inc. Microfluidization of radioactive calcium/oxyanion-containing particles
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
HUT72323A (en) * 1993-01-25 1996-04-29 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
JPH0797340A (en) * 1993-06-03 1995-04-11 Terumo Corp Mri contrast medium composition
AU6766494A (en) * 1994-04-11 1995-10-30 Mallinckrodt Medical, Inc. Microfluidization of calcium/oxyanion-containing particles
DE19500665A1 (en) * 1995-01-12 1996-07-18 Axel Prof Dr Haase Process for the spatially resolving imaging of an area of a biological object with the help of electromagnetic rays using contrast media
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
CN1138825C (en) * 1995-07-12 2004-02-18 丸尾钙株式会社 Additive for synthethic resins and synthetic resin compositions
PT904113E (en) * 1996-03-05 2004-09-30 Acusphere Inc FLUORATED GASES MICROENCAPSULATED FOR USE AS IMAGE ACQUISITIVE AGENTS
DE29608321U1 (en) * 1996-05-08 1996-08-08 Aesculap Ag Marker element
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US7229413B2 (en) 1996-11-06 2007-06-12 Angiotech Biocoatings Corp. Echogenic coatings with overcoat
US6106473A (en) * 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
EP0950686B1 (en) * 1996-12-27 2004-09-22 Maruo Calcium Company Limited Synthetic resin composition
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
CA2326977A1 (en) * 1998-04-03 1999-10-14 Dupont Pharmaceuticals Company Inorganic material for radioactive drug delivery
US5921933A (en) * 1998-08-17 1999-07-13 Medtronic, Inc. Medical devices with echogenic coatings
US5980863A (en) * 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US6203778B1 (en) 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US8498693B2 (en) * 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
CA2659518A1 (en) 2000-11-20 2002-05-30 Senorx, Inc. Tissue site markers for in vivo imaging
WO2002087629A1 (en) * 2001-04-26 2002-11-07 Analogic Corporation Ct scanner for imaging a preselected portion of a patient
US6975896B2 (en) * 2002-05-23 2005-12-13 Koninklijke Philips Electronics N.V. Fiducial markers for MRI
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
AU2003299565A1 (en) * 2002-11-27 2004-06-23 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
US20040170692A1 (en) * 2003-02-12 2004-09-02 The Curators Of The University Of Missouri Calcium phosphate bodies and a process for making calcium phosphate bodies
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US7081366B2 (en) * 2003-06-02 2006-07-25 Northrop Grumman Corporation Uniform bead dosing from a stable dispersion
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US8142758B2 (en) * 2004-02-20 2012-03-27 Algeta As Alpha-emitting hydroxyapatite particles
CN100574810C (en) * 2005-01-10 2009-12-30 重庆海扶(Hifu)技术有限公司 A kind of grain analog assistant for high-intensity focusing ultrasonic therapy and application thereof
CN100427142C (en) * 2005-01-10 2008-10-22 重庆海扶(Hifu)技术有限公司 Assistant for high-intensity focusing ultrasonic therapy and its screening method
US20100041983A9 (en) * 2005-04-04 2010-02-18 Elisha Rabinovitz Device and method for pathology detection
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US20060293581A1 (en) * 2005-05-12 2006-12-28 Sunnybrook And Women's College Health Sciences Centre Marker device for X-ray, ultrasound and MR imaging
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
US7702378B2 (en) 2005-11-17 2010-04-20 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US11241296B2 (en) 2005-11-17 2022-02-08 Breast-Med, Inc. Imaging fiducial markers and methods
BRPI0708636A2 (en) * 2006-03-06 2011-06-07 Symphogen As recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US20070258903A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
GB2442000A (en) * 2006-06-07 2008-03-26 Apatech Ltd Biomedical materials containing gadolinium
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
EP3542748B1 (en) * 2006-12-12 2023-08-16 C. R. Bard, Inc. Multiple imaging mode tissue marker
ES2432572T3 (en) 2006-12-18 2013-12-04 C.R. Bard, Inc. Biopsy marker with imaging properties generated in situ
JP5074803B2 (en) * 2007-03-30 2012-11-14 ニプロ株式会社 Echo-contrastable metal needle
FR2922454B1 (en) * 2007-10-22 2010-01-01 Biomatlante BONE SUBSTITUTE COMPRISING A CONTRAST AGENT, PROCESS FOR PREPARING THE SAME AND USES THEREOF
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
JP5458231B2 (en) * 2008-09-30 2014-04-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 Method for producing fluorapatite powder, fluorapatite powder and adsorption device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US20110190662A1 (en) * 2008-10-01 2011-08-04 Beacon Endoscopic Corporation Rapid exchange fna biopsy device with diagnostic and therapeutic capabilities
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
US20100204570A1 (en) * 2009-02-06 2010-08-12 Paul Lubock Anchor markers
US8623311B2 (en) * 2009-03-03 2014-01-07 Graftys Gallium-doped phosphocalcic compounds
EP2228079A1 (en) * 2009-03-03 2010-09-15 Graftys Gallium-doped phosphocalcic compounds
EP2228080A1 (en) * 2009-03-03 2010-09-15 Graftys Galliated calcium phosphate biomaterials
US8894958B2 (en) * 2009-03-03 2014-11-25 Centre National De La Recherche Scientifique (C.N.R.S.) Galliated calcium phosphate biomaterials
US9039784B2 (en) * 2009-07-28 2015-05-26 Southwest Research Institute Micro-structure particles for load bearing bone growth
CN102573624B (en) * 2009-10-15 2015-07-29 皇家飞利浦电子股份有限公司 The imaging of spectrum magnetic particle
WO2011123613A1 (en) * 2010-04-01 2011-10-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University A dual ct/mri nanoparticle contrast agent
IT1401487B1 (en) * 2010-07-29 2013-07-26 Consiglio Nazionale Ricerche INTRINSICALLY MAGNETIC HYDROXYAPATITIS
US9119887B2 (en) 2010-09-16 2015-09-01 Mo-Sci Corporation Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging
US9849200B2 (en) 2010-09-16 2017-12-26 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US8865123B1 (en) 2010-09-16 2014-10-21 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
WO2014141288A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University The art, method, manner, process and system of a nano-biomineral for multi-modal contrast imaging and drug delivery
WO2014141287A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University The art, method, manner, process and system of multifunctional nanobiomaterial for molecular imaging and drug- delivery
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
US9795455B2 (en) 2014-08-22 2017-10-24 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US11369681B2 (en) 2015-12-03 2022-06-28 Amrita Vishwa Vidyapeetham Radio-wave responsive doped nanoparticles for image-guided therapeutics

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1639040B1 (en) * 1966-07-26 1970-09-03 Westinghouse Electric Corp Crystal as a stimulable medium of an optical transmitter
FR2509611A1 (en) * 1981-07-20 1983-01-21 Fabre Sa Pierre Antacid formulations contg. an apatite - cause less side effects than conventional antacids
EP0093399A1 (en) * 1982-04-30 1983-11-09 GTE Laboratories Incorporated Ce-Mn coactivated fluoroapatite phosphors as the yellow emitting component for high efficacy lamp blends, process for producing same, and a fluorescent lamp containing same
FR2568238A1 (en) * 1984-07-24 1986-01-31 Centre Nat Rech Scient Rare-earth apatite, processes of preparation and applications
EP0210043A2 (en) * 1985-07-19 1987-01-28 Guerbet S.A. Contrast agent for NMR scanning
EP0275215A1 (en) * 1987-01-16 1988-07-20 Guerbet S.A. Contrast agents for the gastrointestinal tract
EP0343934A2 (en) * 1988-05-24 1989-11-29 Anagen (U.K.) Limited Magnetically attractable particles and method of preparation
EP0361797A1 (en) * 1988-09-26 1990-04-04 Kyoto University Heat-generating ceramics body for hyperthermia and method of producing the same
WO1991012212A1 (en) * 1990-02-12 1991-08-22 Thera Patent Gmbh & Co. Kg Gesellschaft Für Industrielle Schutzrechte Apatite glass ceramic

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079124A (en) * 1976-04-21 1978-03-14 Medi-Physics, Inc. Method of preparing X-ray contrast media containing ores of hafnium, tantalum and tungsten
DE2724814C3 (en) * 1977-06-02 1980-03-27 Kulzer & Co Gmbh, 6380 Bad Homburg Preliminary product for the preparation of bone cement
US4243652A (en) * 1978-07-14 1981-01-06 The Procter & Gamble Company Gastrointestinal scanning agent
US4681119A (en) * 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
CA1222947A (en) * 1982-04-23 1987-06-16 Finn N. Christensen Composition and method for investigating alimentary functions
US4635643A (en) * 1982-09-28 1987-01-13 The Medical College Of Wisconsin Research Foundation, Inc. Assay method for the in vivo quantitative determination of mineral content in bone
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
SE463651B (en) * 1983-12-21 1991-01-07 Nycomed As DIAGNOSTIC AND CONTRACTOR
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
GB8522535D0 (en) * 1985-09-11 1985-10-16 Amersham Int Plc Contrast agent
US4709703A (en) * 1985-11-12 1987-12-01 Mayo Foundation Imaging system and method using radiopaque microspheres for evaluation of organ tissue perfusion
DE3542972A1 (en) * 1985-12-05 1987-06-11 Merck Patent Gmbh PHARMACADEPOT
US4888248A (en) * 1986-07-01 1989-12-19 Hidefumi Hirai Colloidal metal dispersion, and a colloidal metal complex
DE3709851A1 (en) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te NMR DIAGNOSTIC LIQUID COMPOSITIONS
US5047031A (en) * 1988-04-20 1991-09-10 Norian Corporation In situ calcium phosphate minerals method
US5009898A (en) * 1988-09-29 1991-04-23 Kabushiki Kaisha Sangi Antimicrobial hydroxyapatite powders and methods for preparing them
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5081997A (en) * 1989-03-09 1992-01-21 Vance Products Incorporated Echogenic devices, material and method
US5236693A (en) * 1990-11-14 1993-08-17 Brigham And Women's Hospital Medical ultrasound contrast agent and method of using same
US5122363A (en) * 1990-12-07 1992-06-16 Board Of Regents, The University Of Texas System Zeolite-enclosed transistion and rare earth metal ions as contrast agents for the gastrointestinal tract
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5179955A (en) * 1991-02-22 1993-01-19 Molecular Biosystems, Inc. Method of abdominal ultrasound imaging
US5330742A (en) * 1991-08-05 1994-07-19 Mallinckrodt Medical, Inc. Methods and compositions for magnetic resonance imaging
US5407659A (en) * 1991-10-22 1995-04-18 Mallinckrodt Medical, Inc. Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5342609A (en) * 1991-10-22 1994-08-30 Mallinckrodt Medical, Inc. Microfluidization of calcium/oxyanion-containing particles

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1639040B1 (en) * 1966-07-26 1970-09-03 Westinghouse Electric Corp Crystal as a stimulable medium of an optical transmitter
FR2509611A1 (en) * 1981-07-20 1983-01-21 Fabre Sa Pierre Antacid formulations contg. an apatite - cause less side effects than conventional antacids
EP0093399A1 (en) * 1982-04-30 1983-11-09 GTE Laboratories Incorporated Ce-Mn coactivated fluoroapatite phosphors as the yellow emitting component for high efficacy lamp blends, process for producing same, and a fluorescent lamp containing same
FR2568238A1 (en) * 1984-07-24 1986-01-31 Centre Nat Rech Scient Rare-earth apatite, processes of preparation and applications
EP0210043A2 (en) * 1985-07-19 1987-01-28 Guerbet S.A. Contrast agent for NMR scanning
EP0275215A1 (en) * 1987-01-16 1988-07-20 Guerbet S.A. Contrast agents for the gastrointestinal tract
EP0343934A2 (en) * 1988-05-24 1989-11-29 Anagen (U.K.) Limited Magnetically attractable particles and method of preparation
EP0361797A1 (en) * 1988-09-26 1990-04-04 Kyoto University Heat-generating ceramics body for hyperthermia and method of producing the same
WO1991012212A1 (en) * 1990-02-12 1991-08-22 Thera Patent Gmbh & Co. Kg Gesellschaft Für Industrielle Schutzrechte Apatite glass ceramic

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARCH. PATHOL. LAB. MED., VOL. 109, NO. 9, PAGE(S) 838-842, 1985, ANDERSON, K, A. BURBACH, J, A. FENTON, L, J. ET AL. 'Idiopathic arterial calcification of infancy in newborn siblings with unusual light and electron microscopic manifestations.' *
DEUT. STOMATOL., VOL. 23, NO. 1, PAGE(S) 8-16, 1973, OELZNER, W. ET AL. 'Struktur und Aufbau menschlichen Zahnsteins' *
HIROSAKI IGAKU, VOL. 28, NO. 2, PAGE(S) 244-51, 1976, KODERA, MASAKATSU ET AL. 'A study of existing states of carbonate in biological apatite by infrared spectroscopy' *
INVEST. RADIOL., VOL. 22, NO. 11, PAGE(S) 853-858, 1987, GAMSU, G. DE GEER, G. CANN, C. MULLER, N. BRITO, A. 'A preliminary study of MRI quantification of simulated calcified pulmonary nodules.' *
J EXP BIOL., VOL. 151, PAGE(S) 371-386, 1990, SPARKS, N, H, C. MOTTA, P, J. SHELLIS, R, P. WADE, V, J. MANN, S. 'AN ANALYTICAL ELECTRON MICROSCOPY STUDY OF IRON-RICH TEETH FROM THE BUTTERFLYFISH CHAETODON-ORNATISSIMUS.' *
J INORG BIOCHEM., VOL. 45, NO. 2, PAGE(S) 129-134. 1992, MAYER, I. DIAB, H. FELNER, I. 'FERRIC IRON IN SYNTHETIC CARBONATE APATITES A MOESSBAUER EFFECT STUDY.' *
MAGNETIC RESONANCE IMAGING vol. 4, no. 4, 1986, US pages 351 - 357 P.F. RENSHAW ET AL. 'Immunospecific NMR contrast agents.' *
NEUROLOGY., VOL. 25, NO. 1, PAGE(S) 48-57, 1975, SMEYERS, VERBEKE, J. MICHOTTE, Y. PELSMAECKERS, J. ET AL. 'The chemical composition of idiopathic nonarteriosclerotic cerebral calcifications.' *
OPHTHALMOLOGY., VOL. 95, NO. 1, PAGE(S) 61-68, 1988, FONT, R, L. BERSANI, T, A. EAGLE, R, C JR. 'Malakoplakia of the eyelid: Clinical, histopathologic, and ultrastructural characteristics.' *

Also Published As

Publication number Publication date
EP0610333A1 (en) 1994-08-17
EP0610333B1 (en) 2001-01-03
AU686523B2 (en) 1998-02-05
ES2152932T3 (en) 2001-02-16
WO1993007905A2 (en) 1993-04-29
US5468465A (en) 1995-11-21
AU7034596A (en) 1997-01-23
US5344640A (en) 1994-09-06
AU674291B2 (en) 1996-12-19
DE69231627T2 (en) 2001-04-26
DE69231627D1 (en) 2001-02-08
ATE198423T1 (en) 2001-01-15
JPH07500823A (en) 1995-01-26
CA2120130A1 (en) 1993-04-29
US5609850A (en) 1997-03-11
AU2886492A (en) 1993-05-21
US5690908A (en) 1997-11-25

Similar Documents

Publication Publication Date Title
WO1993007905A3 (en) Treated apatite particles for medical diagnostic imaging
US4770183A (en) Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
Bloem et al. Gd-DTPA as a contrast agent in CT.
US5055288A (en) Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5069216A (en) Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
Chevallier et al. Tailored biological retention and efficient clearance of pegylated ultra-small MnO nanoparticles as positive MRI contrast agents for molecular imaging
US20090317327A1 (en) Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy
US5407659A (en) Treated calcium/oxyanion-containing particles for medical diagnostic imaging
Chaughule et al. Magnetic nanoparticles as contrast agents for magnetic resonance imaging
Zheng et al. TbF 3 nanoparticles as dual-mode contrast agents for ultrahigh field magnetic resonance imaging and X-ray computed tomography
US5458870A (en) Compositions for magnetic resonance imaging using a manganese oxalate
WO2005067982A2 (en) Methods for imaging the lymphatic system using dendrimer-based contrast agents
Kim et al. Gold nanoparticles coated with gadolinium-DTPA-bisamide conjugate of penicillamine (Au@ GdL) as a T1-weighted blood pool contrast agent
Lee et al. Molecular imaging of CD44-overexpressing gastric cancer in mice using T2 MR imaging
KR20000005194A (en) Method of t1 weighted magnetic resonance imaging of res organs
JPH10120597A (en) Highly accumulating colloidal particle of lymph node
Carr et al. Magnetic Resonance Imaging of the Temporomandibular Joint: Preliminary Work.
ØKSENDAL et al. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging
Øksendal et al. Oral magnetic particles: results from clinical Phase II trials in 216 patients
JP3729514B2 (en) Contrast composition for MRI diagnosis
Xiong et al. An animal model of corpus callosum impingement as seen in patients with normal pressure hydrocephalus
Kumar et al. Fullerene-based nanostructures: a novel high-performance platform technology for magnetic resonance imaging (MRI)
Fernández Barahona Nanomaterials for multimodal molecular imaging
Cormode et al. Nanoparticle contrast agents for cardiovascular medical imaging
Kumar et al. Clinical Applications of Magnetic Resonance Imaging: Tapping the strengths of this imaging technique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 2120130

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992922461

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992922461

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992922461

Country of ref document: EP